



# International Journal of Advanced Research

## Publisher's Name: Jana Publication and Research LLP

www.journalijar.com

### REVIEWER'S REPORT

Manuscript No.: 55135

Title: A DIAGNOSTIC DILEMMA OF JUVENILE OSSIFYING FIBROMA IN A PEDIATRIC PATIENT - A

CASE REPORT

	Rating	Excel.	Good	Fair	Poor
Recommendation:	<u> </u>				
Accept as it is	Originality	•			
Accept after minor revisionYesAccept after major revision  Do not accept ( <i>Reasons below</i> )	Techn. Quality	•			
	Clarity	•			
	Significance		•		

Reviewer Name: Dr. Sireesha Kuruganti Date: 10/12/2025

## Detailed Reviewer's Report

- 1) Summary & Overall Assessment
- \*Manuscript:\* A Diagnostic Dilemma of Juvenile Ossifying Fibroma in a Pediatric Patient A Case Report
- \*Type:\* Case report (single pediatric mandibular JOF; trabecular subtype)
- \*Overall:\* The case is clinically relevant and well-motivated. The manuscript documents a diagnostic pathway from initial misdiagnosis (bacterial sialadenitis) to definitive diagnosis of \*juvenile trabecular ossifying fibroma (JTOF)\* with histopathology and CBCT imaging. However, there are \*major issues\* that must be addressed before publication: (i) internal inconsistencies between planned treatment and conclusions, (ii) insufficient adherence to case-report guidelines (CARE/SCARE), (iii) limited detail in imaging and histopathology documentation, (iv) outdated/heterogeneous classification statements, and (v) editorial/formatting problems (figures, citations, grammar).

*Recommendation:* *Major revision*
## 2) Major Comments (with line references)

### A. Title, Abstract & Framing

## International Journal of Advanced Research

### Publisher's Name: Jana Publication and Research LLP

www.journalijar.com

### REVIEWER'S REPORT

- \*L1-3 (Title formatting):\* Remove extra asterisks and bold markers; standardize to: A Diagnostic Dilemma: Juvenile Ossifying Fibroma of the Mandible in a 7-Year-Old Case Report. Consider specifying "mandible" to enhance discoverability.
- \*L4-19 (Abstract):\*
- \*Content vs. citations:\* Abstract currently includes citation superscripts (e.g., 1,2,3). Most journals discourage references within abstracts. Please \*remove citation markers\* in the Abstract and bring all references to the main text.
- \*Balance & outcomes:\* The abstract notes \*"planned wide surgical excision"\* (L11–12) but the \*Conclusion\* later promotes \*conservative treatment\* (L166–167). This is \*internally inconsistent\*. Please clarify what was actually performed and the rationale, and if conservative management was chosen, explain how it contrasts with the earlier plan.
- \*Key metrics:\* Add succinct quantitative details (e.g., lesion dimensions from CBCT; ESR value; timeframe to diagnosis; follow-up duration if available). This improves clinical utility.

### ### B. Case Presentation Completeness (CARE/SCARE compliance)

- \*L46-74 (Case report & investigations):\*
- Provide a \*timeline\* (symptom onset, antibiotic courses, referrals, imaging dates, biopsy date). CARE guidelines emphasize timelines for clarity.
- Document \*informed consent\* (guardian consent for pediatric case) and any \*institutional/ethics approval\* or waiver. This is essential for publication.
- \*Antibiotics/initial management:\* Specify agents/doses/durations given for presumed sialadenitis (L49–51). Note adverse effects and the decision point to pursue imaging/biopsy.
- \*Laboratory data:\* ESR is stated "elevated" (L73–74). Include the \*actual value\* and relevant differentials (CRP, WBC, cultures) to contextualize the prior \*osteomyelitis\* consideration (L69).
- \*Follow-up:\* The manuscript stops at "scheduled for wide surgical resection" (L85–86). A case report should ideally present \*postoperative findings, \*\*histology of resection, \*\*complications, \*\*recurrence surveillance, and \*\*follow-up duration/outcomes\* (≥6–12 months recommended for JOF due to recurrence risk).

### ### C. Imaging Interpretation & Differential Diagnosis

- \*L63-74; L126-133 (Radiographic features):\*
- The CBCT shows \*mixed radiolucent-radiopaque with ground-glass appearance\* (L66–67). Ground-glass is classically associated with \*fibrous dysplasia (FD)\*; authors do correctly note OF/JOF can be well-demarcated with a radiopaque border distinguishing it from FD (L129–131). Strengthen this section by explicitly contrasting:
- \*Borders\*: JOF typically well-defined and may show a sclerotic rim; FD is ill-defined, blends with normal bone.
- \*Growth pattern: JOF tends to be \*\*concentric/circumscribed\* (L131–132); FD often shows \*expansile\* remodeling without clear boundaries.
- \*Dental effects\*: Root displacement/resorption uncommon in JOF (L127–128) but can occur; note whether present/absent here (you state absent at L59–60).

## International Journal of Advanced Research

### Publisher's Name: Jana Publication and Research LLP

www.journalijar.com

### REVIEWER'S REPORT

- Include \*lesion measurements, \*\*Hounsfield unit ranges\* (if available), and \*specific CBCT planes\* with annotated arrows (body, angle, ramus; L70–72).
- The mention of \*periosteal new bone formation\* (L65) and \*multiple small radiolucent areas\* suggestive of \*chronic osteomyelitis\* (L69) should be reconciled by explaining why osteomyelitis was excluded (e.g., lack of sequestra, clinical signs, labs, biopsy findings).

### ### D. Histopathology Depth & Documentation

- \*L76-86 (Biopsy & H&E):\*
- Histology is described as \*fibrillary osteoid and woven bone in a cellular storiform stroma with "paint-brush" osteoid—consistent with \*\*JTOF\*. To strengthen:
  - Add \*magnification levels\* (×4/×10/×40) and \*scale bars\* on micrographs (L88; Figure 7).
- Describe \*osteoblastic rimming, \*\*giant cells, \*\*mitotic activity\* (you mention some of these at Figure 7; please bring into text with quantified description).
- Consider reporting \*Ki-67 labeling index\* for proliferation, and \*SATB2\* (osteoblastic differentiation) where available. While \*IHC is not mandatory\*, a Ki-67 index may help discuss aggressiveness and recurrence risk in JOF.
- Clarify whether \*psammomatous calcifications\* were \*absent\* (supporting trabecular variant); you mention psammomatous calcifications as pathognomonic for PsJOF (L139–141) but do not state their presence/absence in this case explicitly.

### ### E. Treatment Strategy & Internal Consistency

- \*L85-86 (Planned wide resection)\* vs. \*L151-159; L166-167 (Conservative excision):\*

There is a \*conceptual conflict\* between recommending \*en bloc resection with margins\* (L151–153) and concluding with \*conservative treatment\* to preserve tooth germs (L166–167). Please:

- 1. \*State clearly\* what was performed (curettage + peripheral ostectomy? Marginal resection? Segmental resection? Reconstruction?) and \*why\* (age, lesion extent, cortical status, proximity to tooth buds).
- 2. Provide \*post-operative images\* and \*follow-up results\* (clinical/radiographic at 6, 12 months).
- 3. Align the \*Conclusion\* with the \*actual management\* and the \*literature\* cited.

### ### F. Literature, Classification & Citations

- \*L92–101; L99–104; L143–159 (WHO classification & behavior):\*
- You cite \*WHO 2005\* (L93–94). Please \*update to WHO 2017 Head & Neck Tumors\* classification (and subsequent updates), which more consistently delineate \*ossifying fibroma\* and its juvenile variants within fibro-osseous lesions of the craniofacial skeleton. Replace or complement 2005 references with 2017/2022 authoritative sources and clarify terminology (e.g., "juvenile ossifying fibroma" vs. older "juvenile aggressive ossifying fibroma").
- Support statements like \*radiotherapy contraindication\* (L153) and \*risk of sarcomatous transformation on long-term recurrence\* (L150) with \*high-quality peer-reviewed citations. Where you currently cite conference/research-sharing links (e.g., L185–188; L233–234), please replace with \*\*indexed journal articles\*.

## International Journal of Advanced Research

### Publisher's Name: Jana Publication and Research LLP

www.journalijar.com

### **REVIEWER'S REPORT**

- \*Recurrence rates:\* Provide a \*range\* with \*citations\* for JPOF vs JTOF recurrence (you note higher in JPOF at L104). Include \*time-to-recurrence\* data from robust reviews to contextualize your follow-up recommendations.

### ### G. Figures, Captions & Technical Quality

- \*L61-74; L75 onward (Figures 1-7):\*
- \*Numbering is inconsistent\* (Figures 1–5 appear out of order; "Figure 4" and "Figure 5" captions are embedded around L73 but the images are not clearly placed). Please \*renumber sequentially\* and ensure each figure is \*called out in the text\* in order.
- Replace placeholder/HTML "javascript:void(0)" text (L62; L73) with proper \*figure captions\*.
- Add \*scale bars, \*\*magnification, \*\*plane identifiers\* (axial/coronal), \*windowing, and \*\*arrows/labels\* indicating key features (cortical expansion, ground-glass areas, radiolucent foci).
- Improve \*image resolution\* and remove redundant views; ensure patient identifiers are masked.

### ### H. Language, Style & Formatting

- Multiple spacing/typos: e.g., \*"makeslong"\* (L7), \*"evaluationand"\* (L16), \*"hemimandible"\* use is acceptable but consider "left hemimandible" standardized phrasing (L53–54), \*"BIBILOGRAPHY"\* (L171) → "Bibliography" or "References".
- Standardize terms: \*"trabecular juvenile ossifying fibroma (JTOF)"\* vs \*"juvenile trabecular ossifying fibroma (JTOF)"\*—pick one and use consistently.
- Ensure \*abbreviation expansion\* at first use (IOPAR, OPG, CBCT, ESR).

#### ---

### ## 3) Minor Comments (line-specific)

- \*L20–21 (Keywords):\* Add \*"mandible," "CBCT," "fibro-osseous lesion," "pediatric."\* Separate with semicolons and correct spacing: "juvenile ossifying fibroma; juvenile trabecular ossifying fibroma; juvenile psammomatoid ossifying fibroma".
- \*L35–38:\* When stating \*site predilection\* (JPOF orbit/sinuses; JTOF jaws), add a supporting \*recent systematic review\* reference and clarify that both can occur in jaws and sinonasal regions.
- \*L47–51:\* Clarify \*referral pathway\* (pediatrics → pedodontics) and \*reason\* for re-evaluation.
- \*L55–60:\* Intraoral findings: Consider adding \*periodontal status, \*\*pulp vitality, and \*\*percussion/sensibility tests\*—even if normal, this strengthens the dental context.
- \*L63–67:\* Report \*lesion size\* (anteroposterior × buccolingual × superoinferior), and \*effects on inferior alveolar canal, \*\*mental foramen, \*\*condyle/coronoid\* (you mention involvement; quantify).
- \*L76–79:\* Biopsy: Add \*instrument sizes, \*\*biopsy site, \*\*complications, and \*\*post-biopsy care\*.
- \*L133–141:\* Distinguishing features: Consider a \*table\* summarizing \*JPOF vs JTOF\* (age, site, histology, recurrence).

## International Journal of Advanced Research

### Publisher's Name: Jana Publication and Research LLP

www.journalijar.com

#### REVIEWER'S REPORT

- \*L143–159:\* Treatment paragraph: Clearly \*stratify\* options by \*lesion extent\* (small, well-circumscribed → curettage + peripheral ostectomy; large with cortical perforation → marginal resection; very extensive or recurrent → segmental resection + reconstruction).
- \*L161–168 (Conclusion):\* Align with the \*actual case management\* and \*follow-up\*; avoid general statements that conflict with earlier content.

---

- ## 4) Ethical & Reporting Considerations
- Include a statement on \*patient/guardian informed consent\* for publication of case details and images.
- If applicable, add \*IRB/ethics committee approval\* or a \*statement of exemption\*.
- Consider following the \*CARE\* (Consensus-based Clinical Case Reporting) checklist for completeness (timeline, diagnostic challenges, patient perspective, interventions, outcomes, and follow-up).

---

- ## 5) Suggested Structural Edits
- 1. \*Abstract: \* Remove citations, add outcomes/measurements, reconcile treatment message.
- 2. \*Introduction:\* Update WHO classification; tighten epidemiology with recent data; clearly define JTOF vs JPOF.
- 3. \*Case Description:\* Expand timeline, labs, imaging metrics; biopsy details; postoperative and follow-up outcomes.
- 4. \*Imaging Section:\* Provide annotated CBCT figures with measurements; articulate differential with FD and osteomyelitis.
- 5. \*Histopathology:\* Enhance figure quality; add magnification/scale; consider Ki-67 if available.
- 6. \*Discussion:\* Resolve treatment philosophy vs. case reality; use contemporary literature; present recurrence data and follow-up recommendations grounded in evidence.
- 7. \*Conclusion:\* Make case-specific, evidence-aligned, and concise.
- 8. \*References:\* Correct "Bibliography," ensure consistency (journal names, DOI/PMID where possible), and replace web portals (ResearchGate/JPMI site links) with \*peer-reviewed, indexed sources\*.

---

- ## 6) Example Edits (Text Snippets)
- > \*Abstract (revised concept):\*

## International Journal of Advanced Research

## Publisher's Name: Jana Publication and Research LLP

www.journalijar.com

### REVIEWER'S REPORT

- > Juvenile ossifying fibroma (JOF) is a rare, benign but locally aggressive fibro-osseous tumor of childhood with a high recurrence rate. We report a 7-year-old girl with a 5-month history of progressive swelling of the left mandible. CBCT demonstrated a well-defined mixed radiolucent-radiopaque lesion with cortical expansion, and incisional biopsy confirmed the trabecular variant of JOF. The patient underwent [insert actual management], with [insert outcomes] at [insert follow-up duration]. Early recognition, precise histopathology, and tailored surgery with long-term surveillance are essential to minimize recurrence in pediatric patients.
- > (No references in abstract.)
- > \*Discussion (differential clarity):\*
- > Although the CBCT showed areas of "ground-glass" attenuation, the lesion's well-defined borders and sclerotic rim favored JOF over fibrous dysplasia. The absence of sequestra and systemic inflammatory markers, combined with histology, excluded chronic osteomyelitis.

- ## 7) Editorial Corrections (Selected)
- Correct typos: \*"makeslong"\*  $\rightarrow$  "makes long" (L7); \*"evaluationand"\*  $\rightarrow$  "evaluation and" (L16); \*"BIBILOGRAPHY"\*  $\rightarrow$  "Bibliography" (L171).
- Standardize abbreviations at first mention: \*IOPAR, \*\*OPG, \*\*CBCT, \*\*ESR\*.
- Ensure \*figure sequence and captions\* are consistent and free of HTML placeholders (L62, L73).

---

- ## 8) Final Recommendation
- \*Minor revision\* required. The case is worthy of publication, but the manuscript must present \*coherent management and updated classification.